Basal cell carcinomas are a type of malignant growth identified with the skin and are generally seen inside all diseases. Basal cell carcinoma ascends because of the uncommon and over the top development of basal cells. As basal cell carcinoma has a slower pace of development, they are treatable and they can cause insignificant harm in the event that they are gotten and early treatment is finished. Purposes behind basal cell carcinoma, different danger variables, and indications help in the early discovery, which helps in the treatment.
An increment in different kinds of skin problems, expanding recurrence of cuticular malignancies is the main considerations affecting the market. Besides, the developing geriatric populace, recurrence ascends in the repayment arrangements leaning toward the patients are supporting the development of the basal cell carcinoma treatment market. Expanding frequencies in skin growths because of different ecological elements like UV openness from the sun are the primary purposes behind skin sicknesses. Additionally, eventual outcomes of the treatment and endorsement time for the medications taking too long are the elements influencing the development of the market contrarily.
The global basal cell carcinoma treatment market is projected to rise at a CAGR of 9.20% during the forecast period of 2017 to 2025 and reach an estimated value of USD 10.14 bn from USD 4.66 bn earned in 2016 by the end of 2025.
The global market for basal cell carcinoma treatment is categorized on the basis of treatment type, end user, and geography. In terms of treatment, the market is classified into surgical, drugs, and others. In terms of surgical treatment, the market is sub-categorized into surgical excision, electrodessication & Cutterage (ED&C), Moh’s Surgery, and Cryosurgery. Based on Drugs, the market is grouped into Advanced Medication, Topical Treatment, and others. Further categorization of others segment includes Laser therapy, specialty clinics, and hospitals.
In light of the treatment type, the surgery segment is expected to hold the larger share and will add to the fullest for the development of the basal cell carcinoma market all around the world. This is significantly credited to various surgeries related to the treatment of basal cell carcinoma combined with a few treatment choices. This has driven the surgeries portion to take a front lead for the development of the worldwide basal cell carcinoma treatment market.
Surgery strategy has been set up in basal cell carcinoma for the proficient and least conceivable repeat rates, most extreme fix rates, and top cosmetic outcomes among all the treatment approach for basal cell carcinoma. It is anticipated that surgery stays predominant throughout the following not many years affirming the strength of the by and large basal cell carcinoma treatment market. Extraction surgeries are by and large suggested for basal cell carcinomas that are probably going to repeat, for example, those that are framed on the chest, back, hands, and feet.
North America holds the dominating piece of the pie for the global basal cell carcinoma market. This is exceptionally upheld because of the great predominance of basal cell carcinoma bringing about interest for quite some time choices. This is one of the unmistakable elements that add to the growth of the global basal cell carcinoma treatment market. Aside from that, Asia-Pacific is expected to develop at a higher speed in the impending a very long time by recording a noteworthy CAGR for the basal cell carcinoma market.
On the other side, the market in Asia Pacific is also expected to witness significant growth during the forecast period on account of major revenue generation from the Australian region. The Australian Government upholds giving school instruction with respect to skin malignant growth events. As Australia has the most elevated frequencies of skin tumors on the planet, Australia has been successfully controlling the prevalence of such malignant growth in the past and with more support, it is likely to improve with time. For people under 40, the frequency rate has dropped from a pinnacle of 13 cases for each 100,000 out of 2002 to an expected 9.4 per 100,000 in every 2016. This might bring new hope for the market growth in the coming years. The Government of Australia recognizes declining the predominance of basal cell carcinoma by offering lively bodies including Sports Medicine Australia's Ultraviolet (UV) Exposure and Heat Illness Guide. Furthermore, in 2016-17, US$ 2.3 Bn will be given to the nearby government in unfastened subsidizing under the Financial Assistance Grant Program that permits the gatherings the adaptability to apportion subsidizing to neighborhood needs.
The competitive landscape of the global basal cell carcinoma treatment market is consolidated in nature on account of the presence of a handful of players. Companies operating in this market are indulging in merger and acquisition activities to gain higher revenues in the forthcoming years. Besides this, extensive research and development technologies, and heavy investments on the same by all players are further expected to intensify the overall market competition in the long run. Some of the notable players of the global basal cell carcinoma treatment market include Mylan N.V., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., F. Hoffmann-La Roche Ltd., and Sun Pharmaceuticals Ltd.
The increasing popularity of farm tractors and collecting hardware is relied upon to help the general farm tire market development, as they are utilized for a long time machines, including nerve-racking, furrowing, plowing, and establishing machines. Developing mindfulness with respect to the significance of motorization in the agriculture area for the expansion of results is helping the development of the market. Demand for mechanically progressed tires, for example, with expanded flexion (IF) and strength farm tires, for example, consolidate tires, sprayer tires, and eco-accommodating tires are additionally expected to contribute toward the extension of the market.
The global basal cell carcinoma treatment market was worth US$4.66 bn and is projected to reach a value of US$10.14 bn by the end of 2025
Basal cell carcinoma treatment market is anticipated to grow at a CAGR of 9.2% during the forecast period
North America accounted for a major share of the global basal cell carcinoma treatment market
Basal cell carcinoma treatment market is driven by increase in geriatric population and rising demand for better disease treatments in emerging economies
Key players in the global basal cell carcinoma treatment market include Mylan N.V., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., F. Hoffmann-La Roche Ltd., and Sun Pharmaceuticals Ltd.
Section 1 Preface
1.1 Report Scope and Market Segmentation
1.2 Research Highlights
Section 2 Assumptions and Research Methodology
2.1 Assumptions
2.2 Research Methodology
Section 3 Executive Summary
3.1 Global Basal Cell Carcinoma Treatment: Market Snapshot
3.2 Market Share Analysis by Region, 2016
3.3 Market Opportunity Map
Section 4 Market Overview
4.1 Market Overview
4.2 Global Basal Cell Carcinoma Treatment Market: Market Indicators
4.3 Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, 2015–2025
4.4 Global Basal Cell Carcinoma Treatment Market: Market Outlook
Section 5 Market Dynamics
5.1 Drivers and Restraints Snapshot Analysis
5.2 Drivers
5.2.1 Changing Environmental Factors
5.2.2 Stringent Regulatory Policies Assuring Better Product Quality
5.2.3 Favorable Reimbursement Scenario
5.2.4 Growing Disease Awareness Initiatives
5.2.5 Rise in Geriatric Population
5.3 Restraints
5.3.1 Lack of Awareness in Developing Countries
5.3.2 High Cost of Treatment
5.4 Opportunities
5.4.1 Emerging Markets in Developing Countries
5.4.2 Alternative Potential Therapies
5.5 Key Trends
5.6 Basal Cell Carcinoma Treatment Market: Value Chain Analysis
5.7 Pipeline Analysis: Basal Cell Carcinoma Market
5.8 Key Success Factors of Top 3 Companies
5.9 Healthcare Overview
Section 6 Basal Cell Carcinoma Treatment Market Analysis, by Treatment
6.1 Introduction
6.2 Global Basal Cell Carcinoma Treatment Market Value Share Analysis, by Treatment
6.3 Basal Cell Carcinoma Treatment Market Forecast, by Treatment
6.3.1 Surgical
6.3.1.1 Surgical Excision
6.3.1.2 Electrodessication & Cutterage (ED&C)
6.3.1.3 Moh's Surgery
6.3.1.4 Cryosurgery
6.3.2 Drugs
6.3.2.1 Topical Treatment
6.3.2.2 Advanced Medication
6.3.2.3 Other
6.3.3 Others
6.3.3.1 Radiation Therapy
6.3.3.2 Photodynamic Therapy (PDT)
6.3.3.3 Laser Therapy
6.4 Market Attractiveness Analysis, by Treatment
Section 7 Basal Cell Carcinoma Treatment Market Analysis, by End User
7.1 Introduction
7.2 Global Basal Cell Carcinoma Treatment Market Value Share Analysis, by End-user
7.3 Basal Cell Carcinoma Treatment Market Forecast, by End-user
7.3.1 Hospitals
7.3.2 Specialty Clinics
7.3.3 Others
7.4Market Attractiveness Analysis, by End-user
Section 8 Basal Cell Carcinoma Treatment Market Analysis, by Region
8.1 Global Basal Cell Carcinoma Treatment Market, Global Market Scenario
8.2 Global Basal Cell Carcinoma Treatment Market Value Share Analysis, by Region
8.3 Basal Cell Carcinoma Treatment Market Forecast, by Region
8.4 Market Attractiveness Analysis, by Region
Section 9 North America Basal Cell Carcinoma Treatment Market Analysis
9.1 Regional Outlook
9.2 Market Overview
9.3 Market Analysis, by Treatment
9.3.1 Market Value Share Analysis, by Treatment
9.3.2 Market Size (US$ Mn) Forecast, by Treatment
9.3.2.1 Surgical
9.3.2.1.1 Surgical Excision
9.3.2.1.2 Electrodessication & Cutterage (ED&C)
9.3.2.1.3 Moh's Surgery
9.3.2.1.4 Cryosurgery
9.3.2.2 Drugs
9.3.2.2.1 Topical Treatment
9.3.2.2.2 Advanced Medication
9.3.2.2.3 Other
9.3.2.3 Others
9.3.2.3.1 Radiation Therapy
9.3.2.3.2 Photodynamic Therapy (PDT)
9.3.2.3.3 Laser Therapy
9.4 Market Analysis, by End-user
9.4.1 Market Value Share Analysis, by End-user
9.4.2 Market Size (US$ Mn) Forecast, by End-user
9.4.2.1 Hospitals
9.4.2.2 Specialty Clinics
9.4.2.3 Others
9.5 Market Analysis, by Country
9.5.1 Market Value Share Analysis, by Country
9.5.2 Market Size (US$ Mn) Forecast, by Country, 2017–2025
9.5.2.1 U.S.
9.5.2.2 Canada
9.6 Market Attractiveness Analysis
9.6.1 by Country
9.6.2 by Treatment
9.6.3 by End-user
Section 10 Europe Basal Cell Carcinoma Treatment Market Analysis
10.1 Regional Outlook
10.2 Market Overview
10.3 Market Analysis, by Treatment
10.3.1 Market Value Share Analysis, by Treatment
10.3.2 Market Size (US$ Mn) Forecast, by Treatment
10.3.2.1 Surgical
10.3.2.1.1 Surgical Excision
10.3.2.1.2 Electrodessication & Cutterage (ED&C)
10.3.2.1.3 Moh's Surgery
10.3.2.1.4 Cryosurgery
10.3.2.2 Drugs
10.3.2.2.1 Topical Treatment
10.3.2.2.2 Advanced Medication
10.3.2.2.3 Other
10.3.2.3 Others
10.3.2.3.1 Radiation Therapy
10.3.2.3.2 Photodynamic Therapy (PDT)
10.3.2.3.3 Laser Therapy
10.4 Market Analysis, by End-user
10.4.1 Market Value Share Analysis, by End-user
10.4.2 Market Size (US$ Mn) Forecast, by End-user
10.4.2.1 Hospitals
10.4.2.2 Specialty Clinics
10.4.2.3 Others
10.5 Market Analysis, by Country
10.5.1 Market Value Share Analysis, by Country
10.5.2 Market Size (US$ Mn) Forecast, by Country, 2017–2025
10.5.2.1 UK
10.5.2.2 Germany
10.5.2.3 France
10.5.2.4 Spain
10.5.2.5 Italy
10.5.2.6 Rest of Europe
10.6 Market Attractiveness Analysis
10.6.1 by Country
10.6.2 by Treatment
10.6.3 by End-user
Section 11 Asia Pacific Basal Cell Carcinoma Treatment Market Analysis
11.1 Regional Outlook
11.2 Market Overview
11.3 Market Analysis, by Treatment
11.3.1 Market Value Share Analysis, by Treatment
11.3.2 Market Size (US$ Mn) Forecast, by Treatment
11.3.2.1 Surgical
11.3.2.1.1 Surgical Excision
11.3.2.1.2 Electrodessication & Cutterage (ED&C)
11.3.2.1.3 Moh's Surgery
11.3.2.1.4 Cryosurgery
11.3.2.2 Drugs
11.3.2.2.1 Topical Treatment
11.3.2.2.2 Advanced Medication
11.3.2.2.3 Other
11.3.2.3 Others
11.3.2.3.1 Radiation Therapy
11.3.2.3.2 Photodynamic Therapy (PDT)
11.3.2.3.3 Laser Therapy
11.4 Market Analysis, by End-user
11.4.1 Market Value Share Analysis, by End-user
11.4.2 Market Size (US$ Mn) Forecast, by End-user
11.4.2.1 Hospitals
11.4.2.2 Specialty Clinics
11.4.2.3 Others
11.5 Market Analysis, by Country
11.5.1 Market Value Share Analysis, by Country
11.5.2 Market Size (US$ Mn) Forecast, by Country, 2017–2025
11.5.2.1 Australia & New Zealand
11.5.2.2 Japan
11.5.2.3 China
11.5.2.4 Rest of APAC
11.6 Market Attractiveness Analysis
11.6.1 by Country
11.6.2 by Treatment
11.6.3 by End-user
Section 12 Latin America Basal Cell Carcinoma Treatment Market Analysis
12.1 Regional Outlook
12.2 Market Overview
12.3 Market Analysis, by Treatment
12.3.1 Market Value Share Analysis, by Treatment
12.3.2 Market Size (US$ Mn) Forecast, by Treatment
12.3.2.1 Surgical
12.3.2.1.1 Surgical Excision
12.3.2.1.2 Electrodessication & Cutterage (ED&C)
12.3.2.1.3 Moh's Surgery
12.3.2.1.4 Cryosurgery
12.3.2.2 Drugs
12.3.2.2.1 Topical Treatment
12.3.2.2.2 Advanced Medication
12.3.2.2.3 Other
12.3.2.3 Others
12.3.2.3.1 Radiation Therapy
12.3.2.3.2 Photodynamic Therapy (PDT)
12.3.2.3.3 Laser Therapy
12.4 Market Analysis, by End-user
12.4.1 Market Value Share Analysis, by End-user
12.4.2 Market Size (US$ Mn) Forecast, by End-user
12.4.2.1 Hospitals
12.4.2.2 Specialty Clinics
12.4.2.3 Others
12.5 Market Analysis, by Country
12.5.1 Market Value Share Analysis, by Country
12.5.2 Market Size (US$ Mn) Forecast, by Country, 2017–2025
12.5.2.1 Brazil
12.5.2.2 Mexico
12.5.2.3 Rest of LATAM
12.6 Market Attractiveness Analysis
12.6.1 by Country
12.6.2 by Treatment
12.6.3 by End-user
Section 13 Middle East & Africa Basal Cell Carcinoma Treatment Market Analysis
13.1 Regional Outlook
13.2 Market Overview
13.3 Market Analysis, by Treatment
13.3.1 Market Value Share Analysis, by Treatment
13.3.2 Market Size (US$ Mn) Forecast, by Treatment
13.3.2.1 Surgical
13.3.2.1.1 Surgical Excision
13.3.2.1.2 Electrodessication & Cutterage (ED&C)
13.3.2.1.3 Moh's Surgery
13.3.2.1.4 Cryosurgery
13.3.2.2 Drugs
13.3.2.2.1 Topical Treatment
13.3.2.2.2 Advanced Medication
13.3.2.2.3 Other
13.3.2.3 Others
13.3.2.3.1 Radiation Therapy
13.3.2.3.2 Photodynamic Therapy (PDT)
13.3.2.3.3 Laser Therapy
13.4 Market Analysis, by End-user
13.4.1 Market Value Share Analysis, by End-user
13.4.2 Market Size (US$ Mn) Forecast, by End-user
13.4.2.1 Hospitals
13.4.2.2 Specialty Clinics
13.4.2.3 Others
13.5 Market Analysis, by Country
13.5.1 Market Value Share Analysis, by Country
13.5.2 Market Size (US$ Mn) Forecast, by Country, 2017–2025
13.5.2.1 South Africa
13.5.2.2 GCC Countries
13.5.2.3 Rest of MEA
13.6 Market Attractiveness Analysis
13.6.1 by Country
13.6.2 by Treatment
13.6.3 by End-user
Section 14 Company Profiles
14.1 Basal Cell Carcinoma Treatment Market Share Analysis, by Company (2016)
14.2 Company Profiles
14.2.1 Sun Pharmaceuticals Ltd.
14.2.1.1 Company Overview (HQ, Business Segments, Employee Strength)
14.2.1.2 Financial Overview
14.2.1.3 Product Portfolio
14.2.1.4 SWOT Analysis
14.2.1.5 Strategic Overview
14.2.2 Valeant Pharmaceuticals International, Inc.
14.2.2.1 Company Overview (HQ, Business Segments, Employee Strength)
14.2.2.2 Financial Overview
14.2.2.3 Product Portfolio
14.2.2.4 SWOT Analysis
14.2.2.5 Strategic Overview
14.2.3 Mylan N.V.
14.2.3.1 Company Overview (HQ, Business Segments, Employee Strength)
14.2.3.2 Financial Overview
14.2.3.3 Product Portfolio
14.2.3.4 SWOT Analysis
14.2.3.5 Strategic Overview
14.2.4 F. Hoffmann-La Roche Ltd.
14.2.4.1 Company Overview (HQ, Business Segments, Employee Strength)
14.2.4.2 Financial Overview
14.2.4.3 Product Portfolio
14.2.4.4 SWOT Analysis
14.2.4.5 Strategic Overview
14.2.5 Merck & Co., Inc.
14.2.5.1 Company Overview (HQ, Business Segments, Employee Strength)
14.2.5.2 Financial Overview
14.2.5.3 Product Portfolio
14.2.5.4 SWOT Analysis
14.2.5.5 Strategic Overview
List of Tables
Table 01: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
Table 02: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Surgical Treatment, 2017–2025
Table 03: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Drugs Treatment, 2017–2025
Table 04: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Other Treatment, 2017–2025
Table 05: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 06: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Region, 2017–2025
Table 07: North America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
Table 08: North America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Surgical Treatment
Table 09: North America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Drugs Treatment
Table 10: North America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Other Treatment
Table 11: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 12: North America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 13: Europe Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
Table 14: Europe Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Surgical Treatment, 2017–2025
Table 15: Europe Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Drugs Treatment, 2017–2025
Table 16: Europe Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Other Treatment, 2017–2025
Table 17: Europe Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 18: Europe Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 19: Asia Pacific Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
Table 20: Asia Pacific Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Surgical Treatment
Table 21: Asia Pacific Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Drugs Treatment, 2017–2025
Table 22: Asia Pacific Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Other Treatment, 2017–2025
Table 23: Asia Pacific Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 24: Asia Pacific Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 25: Latin America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
Table 26: Latin America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Surgical Treatment
Table 27: Latin America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Drugs Treatment
Table 28: Latin America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Other Treatment
Table 29: Latin America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 30: Latin America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 31: Middle East & Africa Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Treatment
Table 32: Middle East & Africa Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Surgical Treatment, 2017–2025
Table 33: Middle East & Africa Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Drugs Treatment, 2017–2025
Table 34: Middle East & Africa Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Other Treatment, 2017–2025
Table 35: Middle East & Africa Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by End-user
Table 36: Middle East & Africa Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Country, 2015–2025
List of Figures
Figure 01: Basal Cell Carcinoma Treatment Market Snapshot
Figure 02: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 03: Market Value Share by Treatment (2016)
Figure 04: Market Value Share by End-user (2016)
Figure 05: Market Value Share by Region (2016)
Figure 06: Global Basal Cell Carcinoma Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 07: Global Basal Cell Carcinoma Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Surgical Treatment, 2015–2025
Figure 08: Global Basal Cell Carcinoma Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Drugs Treatment, 2015–2025
Figure 09: Global Basal Cell Carcinoma Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 10: Global Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Treatment
Figure 11: Global Basal Cell Carcinoma Treatment Market Value Share Analysis, by End-user, 2016 and 2025
Figure 12: Global Basal Cell Carcinoma Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2015–2025
Figure 13: Global Basal Cell Carcinoma Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Specialty Clinics, 2015–2025
Figure 14: Global Basal Cell Carcinoma Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 15: Global Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by End-user
Figure 16: Global Basal Cell Carcinoma Treatment Market Value Share Analysis, by Region, 2016 and 2025
Figure 17: Global Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Region
Figure 18: North America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, 2017–2025
Figure 19: North America Market Attractiveness Analysis, by Country
Figure 20: North America Basal Cell Carcinoma Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 21: North America Basal Cell Carcinoma Treatment Market Value Share Analysis, by End-user, 2016 and 2025
Figure 22: North America Basal Cell Carcinoma Treatment Market Value Share Analysis, by Country, 2016 and 2025
Figure 23: North America Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Treatment
Figure 24: North America Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by End-user
Figure 25: Europe Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, 2017–2025
Figure 26: Europe Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Country
Figure 27: Europe Basal Cell Carcinoma Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 28: Europe Basal Cell Carcinoma Treatment Market Value Share Analysis, by End-user, 2016 and 2025
Figure 29: Europe Basal Cell Carcinoma Treatment Market Value Share Analysis, by Country, 2016 and 2025
Figure 30: Europe Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Treatment
Figure 31: Europe Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by End-user
Figure 32: Asia Pacific Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, 2015–2025
Figure 33: Asia Pacific Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Country
Figure 34: Asia Pacific Basal Cell Carcinoma Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 35: Asia Pacific Basal Cell Carcinoma Treatment Market Value Share Analysis, by End-user, 2016 and 2025
Figure 36: Asia Pacific Basal Cell Carcinoma Treatment Market Value Share Analysis, by Country, 2016 and 2025
Figure 37: Asia Pacific Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Treatment
Figure 38: Asia Pacific Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by End-user
Figure 39: Latin America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, 2015–2025
Figure 40: Latin America Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Country
Figure 41: Latin America Basal Cell Carcinoma Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 42: Latin America Basal Cell Carcinoma Treatment Market Value Share Analysis, by End-user, 2016 and 2025
Figure 43: Latin America Basal Cell Carcinoma Treatment Market Value Share Analysis, by Country, 2016 and 2025
Figure 44: Latin America Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Treatment
Figure 45: Latin America Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by End-user
Figure 46: Middle East & Africa Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, 2015–2025
Figure 47: Middle East & Africa Market Attractiveness Analysis, by Country
Figure 48: Middle East & Africa Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 49: Middle East & Africa Market Value Share Analysis, by End-user, 2016 and 2025
Figure 50: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2025
Figure 51: Middle East & Africa Market Attractiveness Analysis, by Treatment
Figure 52: Middle East & Africa Market Attractiveness Analysis, by End-user
Figure 53: Global Basal Cell Carcinoma Market Share Analysis, by Company (2016)
Figure 54: Sun Pharmaceuticals Ltd Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 55: Sun Pharmaceuticals Ltd Breakdown of Net Sales, By Business Segments, 2017
Figure 56: Sun Pharmaceuticals Ltd Breakdown of Net Sales, by Region, 2017
Figure 57: Sun Pharmaceuticals Ltd R&D Expense (US$ Bn) & Y-o-Y Growth (%), 2015–2017
Figure 58: Valeant Pharmaceuticals International, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 59: Valeant Pharmaceuticals International, Inc. Marketing and R&D Expenses, 2015–2016
Figure 60: Valeant Pharmaceuticals International, Inc. Breakdown of Net Sales, by Region, 2016
Figure 61: Valeant Pharmaceuticals International, Inc. Breakdown of Net Sales, by Business Segment, 2016
Figure 62: Mylan N.V. Marketing and R&D Expenses, 2015–2016
Figure 63: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 64: Mylan N.V. Breakdown of Net Sales, by Region, 2016
Figure 65: F. Hoffmann-La Roche Ltd. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 66: F. Hoffmann-La Roche Ltd. R&D Expenses, 2014–2016
Figure 67: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales, by Region, 2016
Figure 68: Merck & Co., Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 69: Merck & Co., Inc. Breakdown of Net Sales, by Region, 2016
Figure 70: Merck & Co., Inc. Breakdown of Net Sales, by Business Segment, 2016
Figure 71: Merck & Co., Inc. R&D Expense (US$ Bn) & Y-o-Y Growth (%), 2014–2016
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Basal Cell Carcinoma Treatment Market Report, 2017-2025
